bought at 58, page-26

Damage control...good:

Sydney - Thursday - Sep 4: (RWE Australian Business News) -
Progen Pharmaceuticals Ltd (ASX:PGL) today announced that with the
wind-down of the PATHWAY phase 3 clinical trial substantially complete,
7.5 FTE positions had been made redundant, or 25pc of the workforce
excluding the PharmaSynth manufacturing business.
The majority of the redundancies have been made in
administration, corporate and manufacturing regulatory affairs. These
positions are no longer required to support ongoing activities.
In addition, Prof John Zalcberg has tendered his resignation as
a non-executive director.
"Prof Zalcberg has served as a director for over 13 years. His
expertise as a leading oncology clinician has been invaluable to the
board and the entire company, and he has made a very significant
contribution to Progen and we acknowledge that contribution," chairman
Dr Mal Eutick said.